Mitochondrial diseases: a review
Mitochondria are organelles responsible for production of mostenergy through oxidative phosphorylation process (OXPHOS). Itcontains a double strand DNA (mitDNA) of about 16,500 bp encodingtwo ribosomal RNAs and 37 mitochondrial proteins. Mutation inmitDNA may result in multisystem syndromes known as...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Israelita de Ensino e Pesquisa Albert Einstein
2006-12-01
|
Series: | Einstein (São Paulo) |
Subjects: | |
Online Access: | http://www.einstein.br/revista/arquivos/PDF/Einstein_vol4_n4_2006_p343.pdf |
id |
doaj-9f462a6301404a55a6fd3473bb366b6a |
---|---|
record_format |
Article |
spelling |
doaj-9f462a6301404a55a6fd3473bb366b6a2020-11-24T23:27:02ZengInstituto Israelita de Ensino e Pesquisa Albert EinsteinEinstein (São Paulo)1679-45082006-12-0144343350Mitochondrial diseases: a reviewDaniel JarovskyPedro ShiozawaUlisses Augusto Correia RosalinoMirna Duarte BarrosMitochondria are organelles responsible for production of mostenergy through oxidative phosphorylation process (OXPHOS). Itcontains a double strand DNA (mitDNA) of about 16,500 bp encodingtwo ribosomal RNAs and 37 mitochondrial proteins. Mutation inmitDNA may result in multisystem syndromes known asmitochondrial diseases, affecting predominantly tissues thatrequire high levels of ATP such as skeletal muscle (mitochondrialmyopathies), brain (e.g. MELAS, MERRF, LHON e NARP), liver,kidney (Fanconi syndrome), heart and endocrine glands (Pearsonsyndrome). A case of mitochondrial disease was first reported in1962 and correlation of such disease with mutations in mitDNAgained scientific importance in late 1980’s. There are 150 alterationsreported in mitDNA capable of producing metabolic dysfunctionsof clinical relevance. To date, no standard protocol for diagnosis ofmitochondrial diseases has been established, partially due to thewide amplitude of clinical manifestation generally observed. Acombined analysis of clinical data, biochemical, morphologicaland laboratory tests must be performed to evaluate mitochondrialrespiratory chain activity and integrity of nuclear and mitochondrialgenomes. Currently, there are no effective treatments availablefor mitochondrial diseases, but only palliative therapeutics usingconventional strategies to relieve symptoms. Thus, gene therapyemerges as potential therapeutic strategy for more efficienttreatment of mitochondrial diseases.http://www.einstein.br/revista/arquivos/PDF/Einstein_vol4_n4_2006_p343.pdfMitochondrial diseasesMetabolic diseasesReview |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Daniel Jarovsky Pedro Shiozawa Ulisses Augusto Correia Rosalino Mirna Duarte Barros |
spellingShingle |
Daniel Jarovsky Pedro Shiozawa Ulisses Augusto Correia Rosalino Mirna Duarte Barros Mitochondrial diseases: a review Einstein (São Paulo) Mitochondrial diseases Metabolic diseases Review |
author_facet |
Daniel Jarovsky Pedro Shiozawa Ulisses Augusto Correia Rosalino Mirna Duarte Barros |
author_sort |
Daniel Jarovsky |
title |
Mitochondrial diseases: a review |
title_short |
Mitochondrial diseases: a review |
title_full |
Mitochondrial diseases: a review |
title_fullStr |
Mitochondrial diseases: a review |
title_full_unstemmed |
Mitochondrial diseases: a review |
title_sort |
mitochondrial diseases: a review |
publisher |
Instituto Israelita de Ensino e Pesquisa Albert Einstein |
series |
Einstein (São Paulo) |
issn |
1679-4508 |
publishDate |
2006-12-01 |
description |
Mitochondria are organelles responsible for production of mostenergy through oxidative phosphorylation process (OXPHOS). Itcontains a double strand DNA (mitDNA) of about 16,500 bp encodingtwo ribosomal RNAs and 37 mitochondrial proteins. Mutation inmitDNA may result in multisystem syndromes known asmitochondrial diseases, affecting predominantly tissues thatrequire high levels of ATP such as skeletal muscle (mitochondrialmyopathies), brain (e.g. MELAS, MERRF, LHON e NARP), liver,kidney (Fanconi syndrome), heart and endocrine glands (Pearsonsyndrome). A case of mitochondrial disease was first reported in1962 and correlation of such disease with mutations in mitDNAgained scientific importance in late 1980’s. There are 150 alterationsreported in mitDNA capable of producing metabolic dysfunctionsof clinical relevance. To date, no standard protocol for diagnosis ofmitochondrial diseases has been established, partially due to thewide amplitude of clinical manifestation generally observed. Acombined analysis of clinical data, biochemical, morphologicaland laboratory tests must be performed to evaluate mitochondrialrespiratory chain activity and integrity of nuclear and mitochondrialgenomes. Currently, there are no effective treatments availablefor mitochondrial diseases, but only palliative therapeutics usingconventional strategies to relieve symptoms. Thus, gene therapyemerges as potential therapeutic strategy for more efficienttreatment of mitochondrial diseases. |
topic |
Mitochondrial diseases Metabolic diseases Review |
url |
http://www.einstein.br/revista/arquivos/PDF/Einstein_vol4_n4_2006_p343.pdf |
work_keys_str_mv |
AT danieljarovsky mitochondrialdiseasesareview AT pedroshiozawa mitochondrialdiseasesareview AT ulissesaugustocorreiarosalino mitochondrialdiseasesareview AT mirnaduartebarros mitochondrialdiseasesareview |
_version_ |
1725553633233207296 |